The Efficacy Of The Unified Transdiagnostic Treatment for Irritable Bowel Syndrome
Not Applicable
- Conditions
- Irritable bowel syndrome.irritable colon
- Registration Number
- IRCT2017010431765N1
- Lead Sponsor
- Vice chancellor for research of Kashan University of Medical Sciences and Health Services
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
diagnosis IBS based on the criteria of Rome III; aged between 18 and 40 years; satisfaction and commitment to participate in the study
Exclusion criteria: get interventions psychological treatment in the past year and the time of the study; history of alcohol abuse or drugs; two sessions of absence for each patient.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Depression. Timepoint: Before intervention, After intervention, One month after intervention. Method of measurement: subscale depression dass-42.;Anxiety. Timepoint: Before intervention, After intervention, One month after intervention. Method of measurement: subscale anxiety dass-42.;Stress. Timepoint: Before intervention, After intervention, One month after intervention. Method of measurement: subscale stress dass-42.;Emotion regulation. Timepoint: Before intervention, After intervention, One month after intervention. Method of measurement: emotion regulation questionnaire.;Severity of symptoms in patients with irritable bowel syndrome. Timepoint: Before intervention, After intervention, One month after intervention. Method of measurement: IBS Symptom Severity Scoring.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of the Unified Protocol for transdiagnostic treatment in IBS patients with comorbid anxiety and depression?
How does the Unified Protocol compare to standard CBT or pharmacotherapy for IBS in reducing anxiety, stress, and depression symptoms?
Are there specific biomarkers associated with improved emotion regulation and clinical outcomes in IBS patients undergoing transdiagnostic treatment?
What are the potential adverse events of the Unified Protocol for IBS treatment and how do they compare to pharmacological interventions?
What combination therapies or adjunctive treatments have been explored alongside transdiagnostic approaches for managing IBS subtypes?